secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001664710-25-000029
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros announces positive Phase 1 results for KER-065; plans Phase 2 in DMD in Q1 2026
--------------------------------------------------------------------------------

- KER-065 generally well-tolerated; no serious adverse events or dose-limiting toxicities reported.
- Evidence of activin inhibition: increases in BSAP, adiponectin, and bone density; decreases in CTX, leptin, and fat mass.
- Body composition changes included increased muscle mass and reduced fat mass consistent with activin inhibition.
- Company expects to initiate Phase 2 trial in Duchenne muscular dystrophy in Q1 2026 after regulatory engagement.
- Phase 1 data cut-off Feb 6, 2025; multiple ascending dose period through Day 85 completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000029/0001664710-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000029/kros-20250331.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer